Meltzer E O, Storms W W, Pierson W E, Cummins L H, Orgel H A, Perhach J L, Hemsworth G R
Allergy and Asthma Medical Group and Research Center, San Diego, Calif. 92123.
J Allergy Clin Immunol. 1988 Sep;82(3 Pt 1):447-55. doi: 10.1016/0091-6749(88)90018-8.
Azelastine is a chemically novel medication that has been demonstrated to be clinically effective for asthma and seasonal allergic rhinitis. In a 10-week, multicenter, double-blind, placebo-controlled, crossover study, the efficacy and safety of azelastine, 1 mg and 2 mg twice daily, were evaluated in 192 patients with symptoms of perennial allergic rhinitis. Patients maintained daily symptom and adverse-experience diaries and were evaluated every 2 weeks by the investigators. Pseudoephedrine, 30 mg, was provided as backup medication. Amelioration of most individual symptoms and a decrease in the total symptom scores were observed with both dosages of azelastine; greater improvement with 2 mg twice daily than with 1 mg twice daily, was observed. Nasal congestion, as a symptom and as reflected by rhinomanometric assessment, was the least improved parameter. Backup decongestant medication decreased during treatment with azelastine and increased during the placebo regimen. There were no major adverse effects.
氮卓斯汀是一种化学结构新颖的药物，已被证明对哮喘和季节性过敏性鼻炎具有临床疗效。在一项为期10周的多中心、双盲、安慰剂对照、交叉研究中，对192例常年性过敏性鼻炎症状患者评估了每日两次服用1毫克和2毫克氮卓斯汀的疗效和安全性。患者记录每日症状和不良经历日记，研究人员每2周对其进行评估。提供30毫克伪麻黄碱作为备用药物。两种剂量的氮卓斯汀均观察到大多数个体症状有所改善，总症状评分降低；每日两次服用2毫克比每日两次服用1毫克改善更明显。作为一种症状以及通过鼻阻力测量评估所反映的鼻充血，是改善最少的参数。在氮卓斯汀治疗期间备用减充血剂药物用量减少，而在安慰剂治疗期间增加。未出现重大不良反应。
